The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells

被引：0
|
作者：
Shuyu Li
Yan Liang
Manlin Wu
Xiaojing Wang
Haixia Fu
Yuhao Chen
Zhigang Wang
机构：
[1] Inner Mongolia University,College of Life Science
来源：
Cancer Cell International | / 13卷
关键词：
CCI-779 (temsirolimus); mTOR signaling; Cell growth; Liver cancer cell;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells
    Li, Shuyu
    Liang, Yan
    Wu, Manlin
    Wang, Xiaojing
    Fu, Haixia
    Chen, Yuhao
    Wang, Zhigang
    [J]. CANCER CELL INTERNATIONAL, 2013, 13
  • [2] Temsirolimus (CCI-779): Early results of an mTOR inhibitor in renal carcinoma
    Hudes, GR
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 18 - 18
  • [3] Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients
    Peralba, JM
    DeGraffenried, L
    Friedrichs, W
    Fulcher, L
    Grünwald, V
    Weiss, G
    Hidalgo, M
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (08) : 2887 - 2892
  • [4] mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer
    Yu, K
    Toral-Barza, L
    Discafani, C
    Zhang, WG
    Skotnicki, J
    Frost, P
    Gibbons, JJ
    [J]. ENDOCRINE-RELATED CANCER, 2001, 8 (03) : 249 - 258
  • [5] Effects of mTOR inhibitor, rapamycin and the ester analogue CCI-779 on rhabdomyosarcoma.
    Wan, XL
    Kalburgi, S
    Heiman, L
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6179S - 6179S
  • [6] Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
    Chan, S
    Scheulen, ME
    Johnston, S
    Mross, K
    Cardoso, F
    Dittrich, C
    Eiermann, W
    Hess, D
    Morant, R
    Semiglazov, V
    Borner, M
    Salzberg, M
    Ostapenko, V
    Illiger, HJ
    Behringer, D
    Bardy-Bouxin, N
    Boni, J
    Kong, S
    Cincotta, M
    Moore, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5314 - 5322
  • [7] The mTOR inhibitor, CCI-779, restores tamoxifen response in breast cancer cells with high Akt activity
    deGraffenried, L
    Friedrichs, W
    Fulcher, L
    Silva, J
    Roth, R
    Hidalgo, M
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 : S158 - S158
  • [8] Molecular mechanisms of the mTOR inhibitor temsirolimus (CCI-779) antiproliferative effects in mantle cell lymphoma: Induction of cell cycle arrest, autophagy, and synergy with vorinostat (SAHA).
    Yazbeek, Victor Y.
    Georgakis, Georgios V.
    Li, Yang
    Iwado, Eiji
    Kondo, Seiji
    Younes, Anas
    [J]. BLOOD, 2006, 108 (11) : 706A - 706A
  • [9] Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
    Raymond, E
    Alexandre, J
    Faivre, S
    Vera, K
    Materman, E
    Boni, J
    Leister, C
    Korth-Bradley, J
    Hanauske, A
    Armand, JP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) : 2336 - 2347
  • [10] In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model
    Frost, P
    Moatamed, F
    Bai, H
    Shi, YJ
    Gera, J
    Yan, HJ
    Frost, P
    Gibbons, J
    Lichtenstein, A
    [J]. BLOOD, 2004, 104 (13) : 4181 - 4187
12345